• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
Ann Rheum Dis. Jun 2004; 63(6): 665–670.
Published online Mar 22, 2004. doi:  10.1136/ard.2003.016386
PMCID: PMC1755042

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis

Abstract

Background: TNFα blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS).

Objective: To identify parameters predicting the clinical response to TNF blockers in AS.

Methods: Patients with active AS participated in two placebo controlled, randomised trials conducted in Germany with infliximab (n = 69) and etanercept (n = 30), respectively. For inclusion in either trial patients had to have high disease activity (BASDAI [gt-or-equal, slanted]4) and a spinal pain score (numerical rating scale 0–10) [gt-or-equal, slanted]4 despite treatment with NSAIDs. A major clinical response was defined as a 50% improvement of the initial BASDAI (BASDAI 50) after 12 weeks' treatment with active drug. Logistic regression likelihood ratio tests (univariate and multivariate), Student's t test, and χ2 tests were performed.

Results: Univariate analysis showed the following to be predictors of a major response (BASDAI 50) to treatment: shorter disease duration (p = 0.003); lower BASFI (p = 0.007); younger age (p = 0.009); raised ESR (p = 0.033); raised CRP (p = 0.035). After adjustment for disease duration, BASFI, ESR, and CRP, but not age, remained significantly associated. After adjustment for disease duration and for BASFI, ESR, CRP, and in addition, a higher BASDAI were significantly associated with response. The best multivariate model built by stepwise regression contained the covariables disease duration, BASFI, BASDAI, and CRP.

Conclusion: A shorter disease duration, younger age, and a lower BASFI are predictors of a major clinical response to TNF blockers in active AS. Raised CRP and a higher BASDAI may also be valuable predictors. These data need to be confirmed in further studies.

Full Text

The Full Text of this article is available as a PDF (129K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002 Dec;61 (Suppl 3):iii8–ii18. [PMC free article] [PubMed]
  • Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Lamour A, Guillemin F, Youinou P, Le Goff P. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Société de Rhumatologie de l'Ouest. J Rheumatol. 1999 Dec;26(12):2622–2627. [PubMed]
  • Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan;41(1):58–67. [PubMed]
  • Feldtkeller Ernst, Khan Muhammad Asim, van der Heijde Désirée, van der Linden Sjef, Braun Jürgen. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003 Mar;23(2):61–66. [PubMed]
  • Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden Sj, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis. 2002 Dec;61 (Suppl 3):iii40–iii50. [PMC free article] [PubMed]
  • Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000 Jun;43(6):1346–1352. [PubMed]
  • Brandt J, Haibel H, Sieper J, Reddig J, Braun J. Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum. 2001 Dec;44(12):2936–2937. [PubMed]
  • Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. [PubMed]
  • Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003 Jun;48(6):1667–1675. [PubMed]
  • Gorman Jennifer D, Sack Kenneth E, Davis John C., Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349–1356. [PubMed]
  • Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 2001 Sep;44(9):2112–2117. [PubMed]
  • Maksymowych Walter P, Jhangri Gian S, Lambert Robert G, Mallon Cathy, Buenviaje Heidi, Pedrycz Ewa, Luongo Rolfe, Russell Anthony S. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol. 2002 May;29(5):959–965. [PubMed]
  • Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, Euller-Ziegler L, Sibilia J, Perdriger A, Mezières M, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002 Nov;41(11):1280–1285. [PubMed]
  • Bresnihan Barry, Cunnane Gaye. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am. 2003 Feb;29(1):185–202. [PubMed]
  • Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286–2291. [PubMed]
  • Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994 Dec;21(12):2281–2285. [PubMed]
  • Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994 Sep;21(9):1694–1698. [PubMed]
  • MacKay K, Mack C, Brophy S, Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum. 1998 Dec;41(12):2263–2270. [PubMed]
  • Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001 Aug;44(8):1876–1886. [PubMed]
  • Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003 Feb;62(2):97–99. [PMC free article] [PubMed]
  • Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, Van Der Heijde D. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 2003 Apr;48(4):1126–1136. [PubMed]
  • Braun J, Bollow M, Eggens U, König H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum. 1994 Jul;37(7):1039–1045. [PubMed]
  • Marc V, Dromer C, Le Guennec P, Manelfe C, Fournie B. Magnetic resonance imaging and axial involvement in spondylarthropathies. Delineation of the spinal entheses. Rev Rhum Engl Ed. 1997 Jul-Sep;64(7-9):465–473. [PubMed]
  • Bollow M, Enzweiler C, Taupitz M, Golder W, Hamm B, Sieper J, Braun J. Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S167–S174. [PubMed]
  • Braun J, Pham T, Sieper J, Davis J, van der Linden Sj, Dougados M, van der Heijde D. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003 Sep;62(9):817–824. [PMC free article] [PubMed]

Figures and Tables

Figure 1
Relationship between disease duration and proportion of patients (%) who achieved a BASDAI 50 response after 12 weeks. Here, patients (n = 99) were grouped into three blocks of disease duration ([less-than-or-eq, slant]10 years, 11–20 years, >20 years). ...
Figure 2
Relationship between functional status (BASFI) and proportion of patients (%) who achieved a BASDAI 50 response after 12 weeks. Patients (n = 99) were grouped into blocks of various BASFI scores. Patients with lower BASFI scores (that is, better functional ...
Figure 3
Relationship between disease activity (BASDAI) and proportion of patients (%) who achieved a BASDAI 50 response after 12 weeks. Patients (n = 99) were grouped into blocks of various BASDAI scores. Patients with a BASDAI >5 had a significantly ...
Figure 4
Probability of a BASDAI 50 response after 12 weeks depending on CRP levels at baseline and disease duration. The three curves were calculated by bivariate logistic regression analysis. They represent the expected probabilities of response for three selected ...

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links